

Charity registration number 1141583 (England and Wales)

Company registration number 07564771



the genetic conditions support network

---

**GENE PEOPLE**

**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 MARCH 2025**



# GENE PEOPLE

## LEGAL AND ADMINISTRATIVE INFORMATION

---

Trustees	Ms A Patel	
	Mr A J Kent OBE	
	Mr D Ansel	
	Mr S Mitra	
	Mr C J Conway	
	Dr N V Taverner	
	Dr C Hilcenko	(Appointed 18 December 2024)
	Dr C Steward	
	Mr N L Nicholls	
Charity number (England and Wales)	1141583	
Company number	07564771	
Registered office	Nightingale House 46-48 East Street Epsom Surrey United Kingdom KT17 1HQ	
Independent examiner	Hazel Day Xeinadin Nightingale House 46-48 East Street Epsom Surrey KT17 1HQ	
Solicitors	Stone King LLP Boundary House 91 Charterhouse St Barbican London EC1M 6HR	

---

# GENE PEOPLE

## CONTENTS

---

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 17

---

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) *FOR THE YEAR ENDED 31 MARCH 2025*

---

The trustees present their annual report and financial statements for the year ended 31 March 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

### **Welcome from the Chair**

This year has been quite tumultuous for healthcare in the UK. We have seen the new 10-year plan for the NHS with its shift in emphasis from treatment to prevention and a commitment to move healthcare out of hospital and closer to home. NHS England and the DHSC are merging. The Government and the pharmaceutical industry have been deadlocked over price negotiations – the list goes on.

For patients and families with rare genetic conditions and the groups that support them all this change has been very unsettling. Although change can often create opportunities, uncertainty about how care and support will be organized in future is stressful.

Throughout the year the team at Gene People have provided continuity, monitoring proposed changes and putting forward the needs and views of our Partnership Network and the families they support to Government, the NHS and to Industry and advocating for positive change.

We have also supported the Network through capacity building workshops and webinars, equipping them with tools that enable them to understand better the changes under way.

For individuals and families our helpline has provided invaluable support for those struggling to find a diagnosis of at a loss as to how to secure the support they need.

Our commitment is to continuity, to being a steady presence supporting our community as we navigate these turbulent times.

Alastair Kent  
Chair of Trustees.

# GENE PEOPLE

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

### Objectives and activities

Gene People has a vision to improve the lives of those affected by a genetic condition through the provision of resources and support both to individuals and families, and to the hundreds of condition-specific charities and patient groups that have been established in the UK. The objectives of the charity are:

- the relief of persons suffering from genetic disorders;
- the advancement of medical research into the causes, cure, prevention or relief of such disorders and the publication of the results of that research;
- to raise awareness and advance the education of the public on the subject of genetic disorders;
- to promote the efficiency and effectiveness of other genetic disorder charities in order to assist them to achieve their charitable purposes.

### Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

### Achievements and performance

#### *Significant activities and achievements against objectives*

Everything Gene People does contributes to achieving three strategic pillars, all of which have been designed to improve the lives of those living with genetic conditions. The three pillars are:

- Support and Information
- Strengthening condition-specific support groups and organisations
- Advocacy and collaboration.

The Trustees agreed the following strategic aims for 2024-25:

- *Maintain focus on income generation through increasing visibility:* the team have improved the visibility of Gene People by a programme of speaking engagements, attending events, responding to consultations and increasing the number of partnerships we are involved in. More details can be found below. As usual, Rare Disease Day was supported by Gene People and our Network
- *Expand diversity of income to include revenues earned through contracts:* Gene People was delighted to undertake contracts with Genomics England Limited and the North West Genomics Medicine Service Alliance
- *Continue to improve and develop the Helpline:* the team have continued to consider ways in which to improve the Helpline and is a member of the Helpline Partnership
- *Hold regular webinars on a range of topics for the Partnership Network:* we held a well-received series of webinars on 'Influencing' which was kindly funded by the BioIndustry Association Rare Disease Industry Group
- *Hold the Gene People Leadership Symposium:* the Symposium took place on 23 Jan 2025 with an audience of condition-specific support groups and charities, healthcare professionals and students, and industry. We are grateful for the secretariat for this event provided by the Association of the British Pharmaceutical Industry
- *Submit responses to consultations with input from our Partnership Network where possible:* Gene People responded to several consultations from NICE, the 10 Year Health Plan and the Law Commission on Disabled Children's Social Care. Volunteer support for this area is being sought
- *Explore ways to both create efficiency in ways of working and better support our individual donors:* after a tendering process supported by Gene People's Trustee for Digital Issues, Donorfy was selected as the new customer relationship management system as it offers ways to increase efficiency and support to donors.

# GENE PEOPLE

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

We are a member of a range of organisations including:

- Association of the British Pharmaceutical Industry Patient Advisory Council
- Association of Genetic Nurses and Counsellors Equity Diversity and Inclusion Subcommittee
- Disabled Children's Partnership
- Genetic Alliance UK
- Helplines Partnership
- NCVO
- NICE Voluntary and Community Sector Forum
- Prescription Charges Coalition
- Specialised Health Care Alliance
- Vascular Voice Network.

Speaking engagements included Advanced Therapies 2024, a conference at the Royal Society of Medicine and The King's Fund Life Sciences Conference.

In addition, the team attended a variety of events and meetings including the Cell and Gene Collective, Festival of Genomics, I am number 17 launch event, NHS Genomics Summit, Patients as Partners, Public Policy Projects Genomics conference, and the Scottish Strategic Network for Genomic Medicine Patient Involvement Advisory Group.

These activities took place alongside the core business of the Helpline, fundraising and running the charity. To focus on the helpline briefly, this year the Gene People genetic counsellor led helpline responded to 141 enquiries from individuals, families and professionals dealing with a genetic condition. Our genetic counsellor spent 82 hours on support calls and sent 230 support emails. Enquirers most often contacted the helpline about genetic testing (30%) and for guidance on how to access clinical genetic services (27%). Emotional support was often needed, and all enquiries were managed with sensitivity and care. Enquiries were made about 70 different genetic conditions, with Cystic Fibrosis being the most common condition enquired about. Many other conditions were only enquired about on one occasion each and are extremely rare diseases. Some of the situations managed were complex and required ongoing support from the helpline genetic counsellor

Our ongoing pre and post contact impact surveys showed that 100% of those enquirers who responded found their contact with the service helpful. Some of the feedback received included:

"This is the most wonderful service for families going through the complications a rare genetic disease/s diagnosis brings. Emily was absolutely lovely and I will be back in touch in the future as this is still a very tricky time for our family. Many thanks to the work you do."

"I cannot praise this service enough. I couldn't find anyone to talk to about my fears who I felt could talk it through with me but from an educated perspective, understanding my situation and validating my feelings, until I found this service. Thank you."

"Thanks again for your help last month. It was a pretty excruciating, isolating time and you made it so easy for me to talk freely - I will never forget your kindness to me."

All of this work is not possible without the kind support of generous donors and funders. While the fundraising environment is challenging, Gene People is delighted to have been supported in 2024-25 by:

Amicus Therapeutics  
GiveAsYouLive givers  
London Marathon Runners  
Parexel International  
Regular and payroll givers

And all those who prefer to remain anonymous.

Everyone at Gene People is deeply grateful for your support. Together, we are Gene People.

# GENE PEOPLE

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 MARCH 2025*

---

Lastly, following the adoption of an Environmental policy which includes a public statement of our carbon emissions. Our emissions for financial year 2023-24 were 2.14 tonnes of CO<sub>2</sub>e. This is due to the number of train journeys taken in the year and one return flight to speak at a conference.

The team have actively contributed to events and meetings organised by these groups as speaker, chair or facilitator. In addition, Gene People has engaged actively with:

- Association of Genetic Nurses and Counsellors
- European Rare Disease Helpline Network
- Public Policy Projects.

We are proud of the level of work the small team has produced during the year.

### **Future Plans**

The Trustees agreed the following strategic aims for 2025-26:

- Maintain focus on income generation
- Expand number of contracts to further diversify income
- Improve the marketing of the Helpline
- Hold the Gene People Leadership Symposium and increase participation
- Further develop efficiencies using technology, such as optimising the database and AI.

# GENE PEOPLE

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

### Financial review

#### *Reserves policy*

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. Trustees recognise that the reserves policy has not been achieved and are committed to progressing towards it.

### Structure, governance and management

The charity is a company limited by guarantee, as defined by the Companies Act 2006.

Gene People changed its name from Genetic Disorders UK (GDUK) in May 2021. The registered charity number (number 1141583) and company limited by guarantee (number 07564771) remained the same. Gene People is governed by its memorandum and articles of association dated 15 March 2011 and revised 30 April 2025. The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Ms A Patel

Dr C Ruff

(Resigned 18 December 2024)

Mr D G Atkins

(Resigned 1 November 2024)

Mr A J Kent OBE

Mr D Ansel

Mr S Mitra

Mr C J Conway

Dr N V Taverner

Dr C Hilcenko

(Appointed 18 December 2024)

Dr C Steward

Mr N L Nicholls

#### *Recruitment and appointment of trustees*

Trustees serve on the board for a period of three years that is renewable. New trustees are appointed by the serving trustees, considering the skills required by the board. New trustees are selected on the basis of their skills and experience and how these will contribute to the charity. They receive an induction that includes onboarding meetings with the Chair and chief executive, as well as access to key documents and previous board minutes.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.



## GENE PEOPLE

### TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

#### *Organisational structure*

The board of trustees meets at least four times a year to review progress and policies via video conferencing. Formal reporting by the chief executive to the trustees takes place regularly at board meetings and informally as appropriate throughout the year.

The systems of control that are designed to provide reasonable assurance against material misstatement or loss include; an annual budget approved by the trustees; regular review of financial results, budget variances and non-financial performance indicators; delegation of authority and segregation of duties; and identification and management of risks.

There are two part-time employees serving as chief executive and genetic counsellor. Other roles are undertaken either as needed on an ad hoc basis or through self-employed consultants.

The trustees' report was approved by the Board of Trustees.



Mr A J Kent OBE  
Trustee

Date: 12 December 2025

# GENE PEOPLE

## INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF GENE PEOPLE

---

I report to the trustees on my examination of the financial statements of Gene People (the charity) for the year ended 31 March 2025.

### Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

### Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the Companies Act 2006.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



**Hazel Day**  
BSc (Hons) FCA DChA  
Xeinadin  
Nightingale House  
46-48 East Street  
Epsom  
Surrey  
KT17 1HQ  
Date: 12.12.2025

# GENE PEOPLE

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 MARCH 2025**

		Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
	Notes						
<b>Income from:</b>							
Donations and legacies	2	53,927	(3,000)	50,927	43,894	9,740	53,634
Other trading activities	3	25,708	-	25,708	27,585	-	27,585
<b>Total income</b>		<u>79,635</u>	<u>(3,000)</u>	<u>76,635</u>	<u>71,479</u>	<u>9,740</u>	<u>81,219</u>
<b>Expenditure on:</b>							
Raising funds	4	29,174	100	29,274	19,736	146	19,882
Charitable activities	5	60,607	-	60,607	44,229	4,000	48,229
<b>Total expenditure</b>		<u>89,781</u>	<u>100</u>	<u>89,881</u>	<u>63,965</u>	<u>4,146</u>	<u>68,111</u>
<b>Net income/(expenditure) and movement in funds</b>		(10,146)	(3,100)	(13,246)	7,514	5,594	13,108
<b>Reconciliation of funds:</b>							
Fund balances at 1 April 2024		<u>17,775</u>	<u>5,594</u>	<u>23,369</u>	<u>10,261</u>	<u>-</u>	<u>10,261</u>
<b>Fund balances at 31 March 2025</b>		<u>7,629</u>	<u>2,494</u>	<u>10,123</u>	<u>17,775</u>	<u>5,594</u>	<u>23,369</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

# GENE PEOPLE

## BALANCE SHEET

AS AT 31 MARCH 2025

	Notes	2025 £	£	2024 £	£
<b>Current assets</b>					
Debtors	11	10,683		17,982	
Cash at bank and in hand		4,774		24,669	
		<u>15,457</u>		<u>42,651</u>	
<b>Creditors: amounts falling due within one year</b>	12	(5,334)		(19,282)	
<b>Net current assets</b>			<u>10,123</u>		<u>23,369</u>
<b>The funds of the charity</b>					
Restricted income funds	14		2,494		5,594
Unrestricted funds	15		7,629		17,775
			<u>10,123</u>		<u>23,369</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2025.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 12 December 2025.



Mr A J Kent OBE  
Trustee

Company registration number 07564771 (England and Wales)

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

---

### 1 Accounting policies

#### Charity information

Gene People is a private company limited by guarantee incorporated in England and Wales. The registered office is Nightingale House, 46-48 East Street, Epsom, Surrey, KT17 1HQ, United Kingdom.

#### 1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

#### 1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

### 1 Accounting policies

(Continued)

#### 1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

#### 1.8 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 2 Income from donations and legacies

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Donations and gifts	53,927	(3,000)	50,927	43,894	9,740	53,634

### 3 Income from other trading activities

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Other income	25,708	27,585

### 4 Expenditure on raising funds

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
<b>Fundraising and publicity</b>						
Staff costs	22,862	-	22,862	16,505	-	16,505
<b>Trading costs</b>						
Other trading activities	6,312	100	6,412	3,231	146	3,377
<b>Total costs</b>	<b>29,174</b>	<b>100</b>	<b>29,274</b>	<b>19,736</b>	<b>146</b>	<b>19,882</b>

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 5 Expenditure on charitable activities

	Awareness and education 2025 £	Relief 2025 £	Total 2025 £	Awareness and education 2024 £	Relief 2024 £	Total 2024 £
<b>Direct costs</b>						
IT costs	1,505	-	1,505	1,345	-	1,345
HR Services	550	-	550	660	-	660
Governance	40	-	40	140	-	140
Insurance	1,764	-	1,764	2,356	-	2,356
Bank charges	64	-	64	90	-	90
Sundry	393	-	393	499	-	499
Travel & subsistence	1,145	-	1,145	1,535	-	1,535
Training & development	113	-	113	-	-	-
	<u>5,574</u>	<u>-</u>	<u>5,574</u>	<u>6,625</u>	<u>-</u>	<u>6,625</u>
<b>Share of support and governance costs (see note 6)</b>						
Support	24,082	29,151	53,233	11,960	26,404	38,364
Governance	1,800	-	1,800	3,240	-	3,240
	<u>31,456</u>	<u>29,151</u>	<u>60,607</u>	<u>21,825</u>	<u>26,404</u>	<u>48,229</u>
<b>Analysis by fund</b>						
Unrestricted funds	31,456	29,151	60,607	17,825	26,404	44,229
Restricted funds	-	-	-	4,000	-	4,000
	<u>31,456</u>	<u>29,151</u>	<u>60,607</u>	<u>21,825</u>	<u>26,404</u>	<u>48,229</u>

### 6 Support costs allocated to activities

	2025 £	2024 £
Staff costs	45,614	38,364
Bookkeeping	3,360	-
Legal & professional	4,259	-
Governance costs	1,800	3,240
	<u>55,033</u>	<u>41,604</u>
<b>Analysed between:</b>		
Awareness and education	25,882	15,200
Relief	29,151	26,404
	<u>55,033</u>	<u>41,604</u>



# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

<b>7</b>	<b>Net movement in funds</b>	<b>2025</b>	<b>2024</b>
		<b>£</b>	<b>£</b>
	The net movement in funds is stated after charging/(crediting):		
	Fees payable for the independent examination of the charity's financial statements	<u>1,800</u>	<u>3,240</u>

### 8 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

### 9 Employees

The average monthly number of employees during the year was:

	<b>2025</b>	<b>2024</b>
	<b>Number</b>	<b>Number</b>
Fundraising	1	1
Charitable	<u>1</u>	<u>1</u>
Total	<u>2</u>	<u>2</u>

<b>Employment costs</b>	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Wages and salaries	62,847	50,973
Social security costs	909	-
Other pension costs	<u>4,720</u>	<u>3,896</u>
	<u>68,476</u>	<u>54,869</u>

There were no employees whose annual remuneration was more than £60,000.

#### Remuneration of key management personnel

The remuneration of key management personnel was as follows:

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Aggregate compensation	<u>37,683</u>	<u>27,816</u>

### 10 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

<b>11 Debtors</b>		
	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
<b>Amounts falling due within one year:</b>		
Trade debtors	2,500	7,625
Other debtors	6,263	8,763
Prepayments and accrued income	1,920	1,594
	<u>10,683</u>	<u>17,982</u>
<b>12 Creditors: amounts falling due within one year</b>		
	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Other taxation and social security	3,709	2,332
Trade creditors	263	87
Other creditors	160	15,723
Accruals and deferred income	1,202	1,140
	<u>5,334</u>	<u>19,282</u>
<b>13 Retirement benefit schemes</b>		
	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
<b>Defined contribution schemes</b>		
Charge to profit or loss in respect of defined contribution schemes	<u>4,720</u>	<u>3,896</u>

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension costs charge represents contributions payable by the group to the funds and amounted to £4,720 (2024: £3,896). There are no contributions payable to the funds at the year end (2024: £436). The expense and liability have been recognised in unrestricted funds.

## 14 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	<b>At 1 April 2024</b>	<b>Incoming resources</b>	<b>Resources expended</b>	<b>At 31 March 2025</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Symposium	<u>5,594</u>	<u>(3,000)</u>	<u>(100)</u>	<u>2,494</u>

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 14 Restricted funds (Continued)

Previous year:	At 1 April 2023 £	Incoming resources £	Resources expended £	At 31 March 2024 £
Symposium	-	5,740	(146)	5,594
Helpline	-	4,000	(4,000)	-
	<u>-</u>	<u>9,740</u>	<u>(4,146)</u>	<u>5,594</u>

### 15 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 April 2024 £	Incoming resources £	Resources expended £	At 31 March 2025 £
General fund	<u>17,775</u>	<u>79,635</u>	<u>(89,781)</u>	<u>7,629</u>

  

Previous year:	At 1 April 2023 £	Incoming resources £	Resources expended £	At 31 March 2024 £
General fund	<u>10,261</u>	<u>71,479</u>	<u>(63,965)</u>	<u>17,775</u>

### 16 Analysis of net assets between funds

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £
<b>At 31 March 2025:</b>			
Current assets/(liabilities)	<u>7,629</u>	<u>2,494</u>	<u>10,123</u>
	<u>7,629</u>	<u>2,494</u>	<u>10,123</u>

  

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
<b>At 31 March 2024:</b>			
Current assets/(liabilities)	<u>17,775</u>	<u>5,594</u>	<u>23,369</u>
	<u>17,775</u>	<u>5,594</u>	<u>23,369</u>

# GENE PEOPLE

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) *FOR THE YEAR ENDED 31 MARCH 2025*

---

### **17 Related party transactions**

There were no disclosable related party transactions during the year (2024 - none).

### **18 Company Status**

The charity is a private company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity.